Comprehensive radiotherapy tracked with longer survival in recurrent glioblastoma leptomeningeal dissemination
In recurrent IDH-wildtype glioblastoma LMD, comprehensive RT and systemic therapy were independently associated with longer survival.
In recurrent IDH-wildtype glioblastoma LMD, comprehensive RT and systemic therapy were independently associated with longer survival.
In randomized phase II I-SABR, four doses of nivolumab added to SABR improved 6-year OS to 69% vs 55% and EFS to 55% vs 32%. The long-term signal is compelling, but OS was a secondary endpoint in a relatively small phase II trial.
In phase III MAVERICK, MRI surveillance without PCI improved cognitive failure-free survival, reduced cognitive failure and toxicity, and preserved current OS, despite more brain metastases. Final OS noninferiority analysis is still pending.
Randomized long-term data link low-dose RT for early knee osteoarthritis with durable symptom relief, less structural progression, lower disability, and fewer knee replacements in KL2 disease, supporting a potential disease-modifying effect.
In AEWS1221, SBRT produced a 2% 3-year local recurrence rate in treated bone metastases. Comprehensive metastasis-directed therapy was also associated with substantially better EFS and OS, although the survival comparison was not randomized.
A prospective phase II study found that 4 Gy response-adapted RT relieved pain in most patients with symptomatic myeloma bone lesions, while only 24% required a second course and no grade 3+ treatment-related toxicity occurred.
Five-year NRG-GU003 results support shorter postprostatectomy RT with preserved patient-reported urinary and bowel outcomes and similar biochemical control, but reveal more physician-reported grade 3 GU toxicity with hypofractionation.
In SPPORT, PAM50 Luminal B tumors derived substantially greater benefit from ADT-based intensification, supporting molecular subtyping as a potential tool for personalizing salvage radiotherapy.
In a small ESTRO poll, subjective and lower-grade adverse events showed substantial disagreement despite shared CTCAE v6.0 definitions.
A simple counting task added about 19 seconds to prolonged DIBH in breast cancer patients after oxygenation and hyperventilation.
Across 286 HDR monotherapy patients, higher EQD2 D90 was not associated with biochemical control or overall survival.
Four-day multicatheter HDR partial-breast irradiation produced 3.8% ipsilateral recurrence at 15 years with exclusively grade 1-2 recorded late toxicity.
In 607 predominantly high-risk patients, 15 Gy HDR boost plus EBRT produced durable six-year disease control with low severe late toxicity.
Motorized probe rotation improved sagittal 3D ultrasound consistency and eliminated significant inter-operator variability seen with manual acquisition.
A portable 49 mT MRI system operated during proton and carbon-ion delivery with stable imaging and minimal dosimetric impact.